



CLIENT CASE STUDY



NeuroMedix

NEUROMEDIX INC.

NeuroMedix was founded by BioQuest in February of 2005 for the purpose of rapidly identifying and developing a lead drug candidate from a class of small molecules licensed from Northwestern University. In keeping with BioQuest’s virtual development model, the plan called for a small private seed round followed by an Initial Public Offering on the TSX Venture exchange. In July, BioQuest successfully raised \$500k in seed financing, which allowed us to assemble a formal management team and board of directors, and prepare a preliminary development plan in preparation for the IPO.

BioQuest had assembled a board of directors by October that included prominent members of the biotechnology industry in Canada and the US.. With the board, CEO and CFO in place, BioQuest then worked closely with the management team to prepare the company for the IPO, which was completed in January 2006, raising gross proceeds of \$3.3 million.

In the subsequent 14 months, through a services agreement, BioQuest worked closely with the NeuroMedix management team and provided the operational support and development experience to achieve the following objectives:

- Demonstrate the efficacy of the company’s lead candidate, Minozac, in an animal model of traumatic brain injury
- Manufacture Minozac under cGMP conditions in multi-kg amounts through a CMO
- Complete toxicology and safety pharmacology studies through a CRO
- File several patent applications to protect Minozac, related compounds, and their uses in neuroinflammatory disorders

With GMP manufacturing and pre-clinical toxicology and safety pharmacology studies completed, Minozac is poised to enter Phase I clinical trials after a CTA is filed with Health Canada.

Company founded	Seed financing	IPO \$3.3M	Pre-clinical studies initiated	Complete manufacturing
2005		2006		2007
Technology licensed	BoD and management secured	Manufacturing initiated	Partnering strategy announced	Complete pre-clinical studies

BioQuest and NeuroMedix have successfully advanced the development program from discovery stage to CTA/IND preparation within 20 months of the initial license agreement, building significant value and advancing Northwestern University’s technology.

For more information, please visit NeuroMedix’s web site at www.neuromedixinc.com.

If you would like an expert opinion on the commercial viability of your new technology, would like to discuss a potential partnership opportunity, or inquire about any of our licensing, acquisition or investment opportunities, please contact us.